Skip to main content

Table 2 P value among methylated genes and EGFR mutation

From: DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

  sFRP1 sFRP2 sFRP5 DKK3 WIF-1 APC CDH-1 EGFR mutation
sFRP1 NA 0.004 0.005 0.008 0.02 <0.0001 0.266 0.005
sFRP2 0.004 NA <0.0001 <0.0001 0.007 <0.0001 <0.0001 0.854
sFRP5 0.005 <0.0001 NA <0.0001 <0.0001 0.06 <0.0001 0.011
DKK3 0.008 <0.0001 <0.0001 NA 0.0001 0.006 <0.0001 0.489
WIF-1 0.02 0.007 <0.0001 <0.0001 NA 0.03 0.02 0.094
APC <0.0001 <0.0001 0.06 0.006 0.03 NA 0.126 0.546
CDH-1 0.266 <0.0001 <0.0001 <0.0001 0.02 0.126 NA 0.592
EGFR 0.005 0.854 0.011 0.489 0.094 0.546 0.592 NA
mutation